Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
Conditions
Interventions
KRT-232
Dasatinib
+1 more
Locations
26
United States
University of Alabama Birmingham
Birmingham, Alabama, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Texas Oncology- Sammons CC at Baylor
Dallas, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Start Date
May 7, 2021
Primary Completion Date
December 31, 2024
Completion Date
June 30, 2026
Last Updated
March 21, 2022
NCT06514534
NCT05143840
NCT06994676
NCT06523556
NCT06236724
NCT04195633
Lead Sponsor
Kartos Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions